LivaNova (LIVN) to Release Quarterly Earnings on Tuesday

LivaNova (NASDAQ:LIVN) is projected to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect LivaNova to post earnings of $0.80 per share and revenue of $324.11 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

LivaNova Stock Down 1.1 %

Shares of LIVN opened at $47.44 on Monday. The business’s 50 day simple moving average is $47.95 and its 200-day simple moving average is $49.60. LivaNova has a 1 year low of $43.15 and a 1 year high of $64.47. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The stock has a market capitalization of $2.58 billion, a price-to-earnings ratio of 112.95 and a beta of 1.00.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Friday, February 14th. Robert W. Baird boosted their price objective on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 price target on shares of LivaNova in a research note on Tuesday, January 28th. Finally, Mizuho cut their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. One analyst has rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $69.17.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.27% of the stock is currently owned by company insiders.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.